What is the most advanced research in the oncology sector? What truly new frontiers are being opened in the fight against cancer? The Forum dedicated to these subjects, “Revolutionary therapies for cancer”, organized by IBSA Foundation, will be held on June 21 in the Auditorium of USI (University of the Italian-speaking part of Switzerland).
In the first part of the Forum, IBSA Foundation will present three international “giants” of cancer research: Carl June, director of the Center for Cellular Immunotherapies of the University of Pennsylvania and pioneer of “CAR-T cells” (autograft of lymphocytes enhanced through genetic engineering); Michael Hall, professor at the Biozentrum of the University of Basel, winner of the prestigious Lasker award and discoverer of the important anti-cancer therapy linked to the inhibition of a protein called TOR; and Alberto Mantovani, professor at the Humanitas University of Milan and scientific director of the Humanitas Research Hospital, who in the 1970s was one of the first people in the world to discover the mechanisms that cancer cells activate to block the natural defences of the body.
In the final part of the meeting, Prof. Solange Peters, the future President of the European Society for Medical Oncology (ESMO), will present an overview on how this pioneering research has been moved to the clinic.
The Forum is organized by IBSA Foundation in collaboration with Andrea Alimonti (USI, IOR and IBSA Foundation) and Franco Cavalli (Foundation for the Institute of Oncology Research – IOR).
This special edition of the IBSA scientific forum will take place within the 15th International Conference on Malignant Lymphoma (ICML), which has become the most important international gathering in the field of research and treatment of lymphoid neoplasms, organized by Professor Cavalli and the Foundation for the Institute of Oncology Research (IOR).
The Forum will be in English and is free, open not only to ICML participants but to anyone interested.
Location: Auditorium USI – Lugano – Switzerland
Date: June 21, 2019
Prof. Dr. Michael Hall, Biozentrum University of Basel, Switzerland
Prof. Alberto Mantovani, Humanitas University, Istituto Clinico Humanitas IRCCS, Milan, Italy
Prof. Carl June, University of Pennsylvania Perelman School of Medicine, Philadelphia, USA
Prof. Solange Peters, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland